»ó´Ü¿©¹é
±â»ç (Àüü 124°Ç)
[Conference Report] DPP-4i+SGLT-2i Ç÷´ç+üÁß+½ÉÀ塤½ÅÀå°ü¸®¿¡ ÃÖÀûÈ­ ÀÌ»óµ· ±âÀÚ 2023-06-05 12:01
[Expert Opinion] ´ç´¢º´ ¸®¾ó¿ùµå °ü¸®Àü·« THE MOST 2023-04-03 15:17
[Interview] ¡°±¹»ê SGLT-2¾ïÁ¦Á¦ À̳ªº¸±Û¸®Ç÷ÎÁø

¿ä´ç¹èÃâ·® ´Ã¸° ±¸Á¶Àû Ư¡¿¡ °­Á¡ÀÖ´Ù¡±

ÀÓ¼¼Çü ±âÀÚ 2023-03-10 15:27
[Sub Story] ¡°¸ÞÆ®Æ÷¸£¹Î, ½ÉÇ÷°üÁúȯ À§Çè°¨¼Ò ÇýÅà °¡´É¡± ÀÌ»óµ· ±âÀÚ 2023-02-07 10:46
[Conference Report] 1ÀÏ 2ȸ DPP-4¾ïÁ¦Á¦ ½ÄÈÄÇ÷´ç ¡æ Ç÷´çº¯µ¿¼º °³¼±¿¡ ÃÖÀûÈ­ ÀÌ»óµ· ±âÀÚ 2023-02-06 17:40
¶óÀÎ
[Conference Report] EASD 2022: ADA/EASD Consensus Report & UKPDS THE MOST 2022-12-05 15:14
[Conference Report] 3Á¦º´¿ë¿ä¹ý, Àå±â°£ È¿°ú ¹× ¾ÈÀü¼º º¸¿© ÀÓ¼¼Çü ±âÀÚ 2022-11-16 11:03
[Sub Story] NAFLD Ä¡·á¿¡ Ƽ¾ÆÁ¹¸®µòµð¿Â°è ÀÌ»óµ· ±âÀÚ 2022-07-04 17:02
[Journal Briefing] ¼¼¸¶±Û·çŸÀÌµå ´ç´¢º´¼º ¸Á¸·º´Áõ ´©¸í ¹þÀ»±î? ÇãÈñÀ± ±âÀÚ 2021-06-17 14:45
[Deep in Guideline] ´ç´¢º´ ¸ÂÃãÄ¡·á ÇâÇØ ÇÑ ¹ß ´õ ÀüÁø Áß ÀÓ¼¼Çü ±âÀÚ 2021-02-02 10:22
¶óÀÎ
[Sub Story] SGLT-2¾ïÁ¦Á¦ÀÇ ¾àÁø...
ASCVD¿¡ À̾î HF¡¤CKD±îÁö
ÀÌ»óµ· ±âÀÚ 2021-01-04 17:44
[Sub Story]
[½ÉºÎÀü ȯÀÚÀÇ ´ç´¢º´ °ü¸® Àü·«]

½ÅÀå±â´É¡¤ºÎÀÛ¿ë À§Çè °í·ÁÇÑ Ä¡·á ÇÊ¿ä

THE MOST 2020-08-13 14:48
[Cover Story] Á¦2Çü´ç´¢º´ 1Â÷Ä¡·á Æз¯´ÙÀÓ

½Å¾à¡¤±¸¾à ´ç±Ç ³õ°í ÇÑÆÇ

ÀÌ»óµ· ±âÀÚ 2020-07-26 18:37
[Sub Story] ¡°Ã³À½ºÎÅÍ º´¿ëÇÏ¶ó¡± ÀÓ¼¼Çü ±âÀÚ 2020-07-26 00:07
[Sub Story] ¿¥Æı۸®Ç÷ÎÁø¡¤¸®³ª±Û¸³Æ¾¡¤¸ÞÆ®Æ÷¸£¹Î ÀÌ»óµ· ±âÀÚ 2020-07-25 23:20
¶óÀÎ
[Drug Review] ÇÁ¸®½ºÅ¸ÀÏ ¸®ºê·¹, Ç÷´çº¯µ¿¼º °ü¸®Àü·«À¸·Î ºÎ°¢ ÀÓ¼¼Çü ±âÀÚ 2020-07-25 15:01
[Interview] Ç÷´çº¯µ¿¼º °ü¸®ÀÇ ½Ã´ë, ¿¬¼ÓÇ÷´çÃøÁ¤(CGM)ÀÌ ÇعýµÈ´Ù ÀÓ¼¼Çü ±âÀÚ 2020-07-25 14:45
[Sub Story] µÑ¶ó±Û·çŸÀ̵尡 ½î¾Æ¿Ã¸° CVOT ÀÌ»óµ· ±âÀÚ 2020-07-19 18:50
[Interview] GLP-1¼ö¿ëüÀÛ¿ëÁ¦

¡°½ÉÇ÷°üÁúȯ 1¡¤2Â÷¿¹¹æ ½Ã´ë ¿¬´Ù¡±

ÀÌ»óµ· ±âÀÚ 2020-07-19 18:49
[Cover Story]

½ÉÀå´ë»çÁõÈıº â±ÈÀÌ ½ÉÀå´ë»çÇРŵ¿

½ÉÀå´ë»çÇÐ °üÁ¡¿¡¼­

½ÉÀå´ë»çÁõÈıº ´Ù½º·Á¾ß

ÀÌ»óµ· ±âÀÚ 2020-07-19 18:44
Back to Top